Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor

Nature Communications

Volumn 5, Issue , 2014, Pages

  Lu, Lu ^a   Liu, Qi ^a   Zhu, Yun ^b   Chan, Kwok Hung ^c   Qin, Lili ^b   Li, Yuan ^a   Wang, Qian ^a   Chan, Jasper Fuk Woo ^c   Du, Lanying ^d   Yu, Fei ^b   Ma, Cuiqing ^b   Ye, Sheng ^b   Yuen, Kwok Yung ^c   Zhang, Rongguang ^b   Jiang, Shibo ^a,b  

^a FUDAN UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HR1P PROTEIN; HR2P PROTEIN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS FUSION INHIBITOR; PROTEIN S II; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; CORONAVIRUS SPIKE GLYCOPROTEIN; PEPTIDE; VIRUS PROTEIN;

ANTIMICROBIAL ACTIVITY; BIOPHYSICS; DISEASE TRANSMISSION; EPIDEMIC; INHIBITOR; MORTALITY; PEPTIDE; PROTEIN; PUBLIC HEALTH; RESPIRATION; SOLUBILITY; VIRUS;

ALPHA HELIX; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL FUSION; CONTROLLED STUDY; CORONAVIRUS; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG SOLUBILITY; DRUG STABILITY; HOST CELL; HUMAN; HUMAN CELL; HYDROPHILICITY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYSICAL CHEMISTRY; PROTEIN DOMAIN; VIRUS ENTRY; VIRUS REPLICATION; VIRUS STRAIN; X RAY CRYSTALLOGRAPHY; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; CRYSTALLOGRAPHY, X-RAY; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR SEQUENCE DATA; PEPTIDES; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRAL FUSION PROTEINS; VIRAL PROTEINS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84893254396     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4067     Document Type: Article

References (63)

1. Peiris, J. S. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-1325 (2003). (Pubitemid 36514862)
2. Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967-1976 (2003). (Pubitemid 36569985)
3. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E. & Fouchier, R. A. M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814-1820 (2012).
4. Gallagher, T. & Perlman, S. Public health: broad reception for coronavirus. Nature 495, 176-177 (2013).
5. WHO. Novel coronavirus infection-update (Middle East respiratory syndrome coronavirus), http://www.who.int/csr/don/2013-11-11/en/index.html, accessed 12 November (2013).
6. Assiri, A. et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 369, 407-416 (2013).
7. Memish, Z. A., Zumla, A. I. & Assiri, A. Middle East respiratory syndrome coronavirus infections in health care workers. N. Engl. J. Med. 368, 2487-2494 (2013).
8. Lu, L., Liu, Q., Du, L. & Jiang, S. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect. 15, 625-629 (2013).
9. Chan, J. F. et al. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J. Infect. 65, 477-489 (2012).
10. Woo, P. C. et al. Comparative analysis of twelve genomes of three novel group 2c and group 2d coronaviruses reveals unique group and subgroup features. J. Virol. 81, 1574-1585 (2013).
11. Chan, J. F. et al. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 21, 544-555 (2013).
12. Lau, S. K. et al. Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. J. Virol. 87, 8638-8650 (2013).
13. Lu, G. et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500, 227-231 (2013).
14. Wang, N. et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 23, 986-993 (2013).
15. Chen, Y. et al. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J. Virol. 87, 10777-10783 (2013).
16. Mou, H. et al. The receptor binding domain of the new MERS coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 87, 9379-9383 (2013).
17. Du, L. et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 87, 9939-9942 (2013).
18. Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251-254 (2013).
19. Chan, K. H. et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J. Infect. 67, 130-140 (2013).
20. Liu, S. et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363, 938-947 (2004). (Pubitemid 38388327)
21. Jiang, S., Lin, K., Strick, N. & Neurath, A. R. HIV-1 inhibition by a peptide. Nature 365, 113 (1993).
22. Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B. & Matthews, T. J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl Acad. Sci. USA 91, 9770-9774 (1994). (Pubitemid 24311889)
23. Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (1997). (Pubitemid 27199898)
24. van, B. S. et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3, e00473-12 (2012).
25. Deng, Y., Liu, J., Zheng, Q., Yong, W. & Lu, M. Structures and polymorphic interactions of two heptad-repeat regions of the SARS virus S2 protein. Structure 14, 889-899 (2006). (Pubitemid 43674104)
26. Xu, Y. et al. Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J. Biol. Chem. 279, 49414-49419 (2004). (Pubitemid 39625827)
27. Supekar, V. M. et al. Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein. Proc. Natl Acad. Sci. USA 101, 17958-17963 (2004). (Pubitemid 40054057)
28. Duquerroy, S., Vigouroux, A., Rottier, P. J., Rey, F. A. & Bosch, B. J. Central ions and lateral asparagine/glutamine zippers stabilize the post-fusion hairpin conformation of the SARS coronavirus spike glycoprotein. Virology 335, 276-285 (2005). (Pubitemid 40544916)
29. Xu, Y. et al. Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J. Biol. Chem. 279, 30514-30522 (2004). (Pubitemid 38937982)
30. Zheng, Q. et al. Core structure of S2 from the human coronavirus NL63 spike glycoprotein. Biochemistry 45, 15205-15215 (2006). (Pubitemid 46032447)
31. Liu, C., Feng, Y., Gao, F., Zhang, Q. & Wang, M. Characterization of HCoV-229E fusion core: implications for structure basis of coronavirus membrane fusion. Biochem. Biophys. Res. Commun. 345, 1108-1115 (2006). (Pubitemid 43776506)
32. Ma, G. et al. Biochemical and biophysical characterization of the transmissible gastroenteritis coronavirus fusion core. Biochem. Biophys. Res. Commun. 337, 1301-1307 (2005). (Pubitemid 41505264)
33. Liu, S., Zhao, Q. & Jiang, S. Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors. Peptide 24, 1303-1313 (2003). (Pubitemid 38045537)
34. Liu, S., Lu, H., Xu, Y., Wu, S. & Jiang, S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 280, 11259-11273 (2005). (Pubitemid 40418432)
35. Tripet, B. et al. Structural characterization of the SARS-coronavirus spike S fusion protein core. J. Biol. Chem. 279, 20836-20849 (2004). (Pubitemid 38656480)
36. Zhu, J. et al. Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem. Biophys. Res. Commun. 319, 283-288 (2004). (Pubitemid 38670191)
37. Chan, J. F. et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J. Infect. Dis. 207, 1743-1752 (2013).
38. Lu, M. & Kim, P. S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 15, 465-471 (1997). (Pubitemid 28035859)
39. Buzon, V. et al. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 6, e1000880 (2010).
40. Otaka, A. et al. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew. Chem. Int. Ed. Engl 41, 2937-2940 (2002).
41. Kilby, J. M. & Eron, J. J. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 348, 2228-2238 (2003). (Pubitemid 36618135)
42. Jiang, S. & Lin, K. Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 gp41 sequence. Peptide Res. 8, 345-348 (1995). (Pubitemid 3022185)
43. Borgo, B. & Havranek, J. J. Automated selection of stabilizing mutations in designed and natural proteins. Proc. Natl Acad. Sci. USA 109, 1494-1499 (2012).
44. Lu, M., Blacklow, S. C. & Kim, P. S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2, 1075-1082 (1995).
45. Chen, X. et al. Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides. J. Biol. Chem. 285, 25506-25515 (2010).
46. Gierer, S. et al. The spike-protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2 and is targeted by neutralizing antibodies. J. Virol. 87, 5502-5511 (2013).
47. Shirato, K., Kawase, M. & Matsuyama, S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol. 87, 12552-12561 (2013).
48. Huyghues-Despointes, B. M., Klingler, T. M. & Baldwin, R. L. Measuring the strength of side-chain hydrogen bonds in peptide helices: the Gln.Asp (i, i4) interaction. Biochemistry 34, 13267-13271 (1995).
49. Oishi, S. et al. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity. J. Med. Chem. 51, 388-391 (2008). (Pubitemid 351252265)
50. Eckert, D. M., Malashkevich, V. N., Hong, L. H., Carr, P. A. & Kim, P. S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99, 103-115 (1999). (Pubitemid 29468634)
51. Ingallinella, P. et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl Acad. Sci. USA 106, 5801-5806 (2009).
52. Chan, J. F. et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J. Infect. 67, 606-616 (2013).
53. McRee, D. E. Practical Protein Crystallography (Academic press, 1999).
54. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997). (Pubitemid 27085611)
55. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004). (Pubitemid 41742764)
56. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
57. Lu, L. et al. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Retrovirology 9, 104 (2012).
58. Chen, Y. H., Yang, J. T. & Chau, K. H. Determination of the helix and beta form of proteins in aqueous solution by circular dichroism. Biochemistry 13, 3350-3359 (1974).
59. Lu, H., Zhao, Q., Xu, Z. & Jiang, S. Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): application for rapid screening of HIV-1 fusion inhibitors. J. Virol. Methods 107, 155-161 (2003). (Pubitemid 36005500)
60. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).
61. He, Y., Lu, H., Siddiqui, P., Zhou, Y. & Jiang, S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J. Immunol. 174, 4908-4915 (2005).
62. Zhao, G. et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol. J. 10, 266 (2013).
63. Jiang, S. et al. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 sixhelix bundle formation and block virus fusion. Antimicrob. Agents Chemother. 48, 4349-4359 (2004). (Pubitemid 39434898)